Bronchiolitis obliterans syndrome (BOS), also called graft-versus-host disease (GVHD) of the lungs, occurs in approximately 5% of patients who were transplanted with donor cells (allogeneic transplant).

2018年11月30日 · Graft-versus-host disease (GVHD) remains a challenge after allogeneic hematopoietic cell transplantation (HCT). GVHD occurs when immunocompetent donor T cells recognize the recipient host as foreign and mount an immune response to allogeneic antigen-bearing cells with subsequent destruction of host tissues.

Recognizing acute GVHD is crucial. Understand how it affects different organs in the body, explore prevention methods, and review common treatment options.

2022年4月30日 · Graft-versus-Host-Disease (GVHD) occurs when transplanted donor cells attack the patient’s body. It can affect virtually every organ in the body and may require prolonged treatment. This presentation reviews the different types of GVHD, symptoms you should watch for and report to your doctor, and the available treatment options.

2024年4月11日 · Chronic GVHD (cGVHD) is the most relevant cause of late non-relapse morbidity and subsequent mortality (approximately 25%) following allo-HCT (Grube et al. 2016).

2023年6月21日 · In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease...

BMT CTN Technical Document Acute & Chronic GVHD Guidance 1. Acute Graft-Vs-Host Disease (GVHD) 1.1. Introduction The Acute GVHD Technical Committee has reviewed and recommends the following procedures for acute GVHD evaluation, data collection, scoring, and final acute GVHD severity evaluation for clinical trials performed through the Network. 1.2.

2020年3月25日 · To standardize GVHD management, the EBMT gives recommendations that apply to the setting of HLA-identical sibling or unrelated donor transplantation of adult patients with haematologic malignancies. Based on published evidence, five members of a task force created 38 statements on prophylaxis of GVHD, drug management, treatment of acute and ...

2021年12月2日 · This randomized phase III trial compared three approaches for chronic GVHD prevention and specifically investigated whether two CNI-free approaches, ex vivo TCD using CD34 selection of PBSC grafts or in vivo TCD of marrow grafts using PTCy alone, could lead to superior control of chronic GVHD without excess disease relapse and mortality.

2020年12月1日 · BMT CTN 1703 builds on recent randomized studies showing encouraging results with the use of PTCy-based GVHD prophylaxis in related and unrelated allogeneic RIC peripheral blood stem cell HCT. Continued enrollment may potentially establish a new standard of care in GVHD prevention and improve outcomes for patients.